LI
ITCI

Leap Investments’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Leap Investments’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-17,400
Closed -$267K – 591
2020
Q1 		$267K Buy
+17,400
New +$378K 0.39% 85

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Leap Investments's ITCI Position: Q2 2020 in Review

Leap Investments sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2020, closing a stake of 17,400 shares — an estimated $267K sold.

Leap Investments first reported a position in ITCI in Q1 2020 and held it in 1 quarter. The position peaked at $267K in Q1 2020. 149 funds tracked by Wall St. Rank hold ITCI as of Q2 2020.

  • Leap Investments reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2020 after selling out during the quarter.
  • Leap Investments sold 17,400 Intra-Cellular Therapies Inc. shares in Q2 2020, an estimated $267K.
  • Leap Investments first reported a position in Intra-Cellular Therapies Inc. in Q1 2020 and held it in 1 quarter.
  • Leap Investments's Intra-Cellular Therapies Inc. position peaked at $267K in Q1 2020.
  • 149 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.